396
Views
2
CrossRef citations to date
0
Altmetric
Case Reports

A case of rheumatoid arthritis with multiple lung rheumatoid nodules successfully treated with tofacitinib

, , , , , , & show all
Pages 1-5 | Received 09 Mar 2020, Accepted 29 May 2020, Published online: 17 Jun 2020

References

  • Enginar AÜ, Nur H, Gilgil E, et al. Accelerated nodulosis in a patient with rheumatoid arthritis. Arch Rheumatol. 2019;34(2):225–228.
  • de Punder YMR, Jansen TLTA, van Ede AE, et al. Etanercept-related extensive pulmonary nodulosis in a patient with rheumatoid arthritis. J Rheumatol. 2015;42(3):398–392.
  • Ziemer M, Müller AK, Hein G, et al. Incidence and classification of cutaneous manifestations in rheumatoid arthritis. J Dtsch Dermatol Ges. 2016;14(12):1237–1246.
  • Highton J, Hung N, Hessian P, et al. Pulmonary rheumatoid nodules demonstrating features usually associated with rheumatoid synovial membrane. Rheumatology (Oxford)). 2007;46(5):811–814.
  • Yousem SA, Colby TV, Carrington CB. Lung biopsy in rheumatoid arthritis. Am Rev Respir Dis. 1985;131(5):770–777.
  • Koslow M, Young JR, Yi ES, et al. Rheumatoid pulmonary nodules : clinical and imaging features compared with malignancy. Eur Radiol. 2019;29(4):1684–1692.
  • Sargin G, Senturk T. Multiple pulmonary rheumatoid nodules. Reumatologia. 2015;53(5):276–278.
  • Shenberger KN, Schned AR. TT. Rheumatoid disease and bronchogenic carcinoma – case report and review of the literature. J Rheumatol. 1984;11:226–228.
  • Kovács A, Baksay B, Cserenyecz A, et al. Occurrence of pulmonary rheumatoid nodules following biological therapies. Clin Rheumatol. 2015;34(9):1639–1642.
  • Kekow J, Welte T, Kellner U, et al. Development of rheumatoid nodules during anti-tumor necrosis factor alpha therapy with etanercept. Arthritis Rheum. 2002;46(3):843–844.
  • Zamora FD, Podgaetz E, Dincer HE. Counterintuitive pulmonary nodules in rheumatoid arthritis. Aech Bronconeumol. 2016;52(6):334–335.
  • Cunnane G, Warnock M, Fye KH, et al. Accelerated nodulosis and vasculitis following etanercept therapy for rheumatoid arthritis. Arthritis Rheum. 2002;47(4):445–449.
  • Sagdeo P, Gattimallanahali Y, Kakade G, et al. Rheumatoid lung nodule. BMJ Case Rep. 2015. DOI:10.1136/bcr-2015-213083
  • Wikaningrum R, Highton J, Parker A, et al. Pathogenic mechanisms in the rheumatoid nodule: Comparison of proinflammatory cytokine production and cell adhesion molecule expression in rheumatoid nodules and synovial membranes from the same patient. Arthritis Rheum. 1998;41(10):1783–1797.
  • De Bandt M, Saint-Marcoux B. Tumour necrosis factor alpha blockade and the risk of vasculitis. Ann Rheum Dis. 2006;65(11):1534–1535.
  • Furst DE, Wallis R, Broder M, et al. Tumor necrosis factor antagonists : different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infection. Semin Arthritis Rheum. 2006;36(3):159–167.
  • Toussirot E, Berthelot JM, Pertuiset E, et al. Pulmonary nodulosis and aseptic granulomatous lung disease occurring in patients with rheumatoid arthritis receiving tumor necrosis factor-alpha-blocking agent: a case series. J Rheumatol. 2009;36(11):2421–2427.
  • Andres M, Vela P, Romera C. Marked improvement of lung rheumatoid nodules after treatment with tocilizumab. Rheumatology (Oxford)). 2012;51(6):1132–1134.
  • Saito-Sasaki N, Sawada Y, Omoto D, et al. A possible pathogenetic role of IL-23/IL-17 axis in rheumatoid nodules in patients with rheumatoid arthritis. Clin Immunol. 2016;170:20–21.
  • Xueyi L, Lina C, Zhenbiao W, et al. Levels of circulating Th17 cells and regulatory T cells in ankylosing spondylitis patients with an inadequate response to anti-TNF-α therapy. J Clin Immunol. 2013;33(1):151–161.
  • Stamp LK, Easson A, Lehnigk U, et al. Different T cell subsets in the nodule and synovial membrane: absence of interleukin-17A in rheumatoid nodules. Arthritis Rheum. 2008;58(6):1601–1608.
  • Clark JD, Flanagan ME, Telliez JB. Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases. J Med Chem. 2014;57(12):5023–5038.
  • Tanaka Y, Yamaoka K. JAK inhibitor tofacitinib for treating rheumatoid arthritis: from basic to clinical. Mod Rheumatol. 2013;23(3):415–424.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.